Nuclear transport as a target for cell growth

Drug Discovery Today

Volumn 8, Issue 2, 2003, Pages 78-85

  Kau, Tweeny R ^a   Silver, Pamela A ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

7 HYDROXYSTAUROSPORINE; APTAMER; IMATINIB; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LEPTOMYCIN B; MIDOSTAURIN; PEPTIDE; PROTEIN KINASE C INHIBITOR; PROTEIN P53; STAUROSPORINE DERIVATIVE; TRANSCRIPTION FACTOR; TUMOR SUPPRESSOR PROTEIN;

ANOREXIA; CELL GROWTH; CELL NUCLEUS; CELLULAR DISTRIBUTION; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CYTOPLASM; HUMAN; INTRACELLULAR TRANSPORT; MALAISE; NAUSEA; NONHUMAN; NUCLEAR LOCALIZATION SIGNAL; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN SECRETION; PROTEIN TARGETING; PROTEIN TRANSPORT; REVIEW; TARGET CELL; TECHNOLOGY; VOMITING;

ACTIVE TRANSPORT, CELL NUCLEUS; ANTIBIOTICS, ANTINEOPLASTIC; CELL NUCLEUS; CLINICAL TRIALS; FATTY ACIDS, UNSATURATED; HUMANS; NEOPLASMS;

EID: 0037439329     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359-6446(02)02562-X     Document Type: Review

References (74)

1. Reichelt R., et al. Correlation between structure and mass distribution of the nuclear pore complex and of distinct pore complex components. J. Cell Biol. 110:1990;883-894.
2. Ohno M., et al. Nucleocytoplasmic transport: the last 200 nanometers. Cell. 92:1998;327-336.
3. Hood J.K., Silver P.A. Diverse nuclear transport pathways regulate cell proliferation and oncogenesis. Biochim. Biophys. Acta. 1471:2000;M31-M41.
4. Ossareh-Nazari B., et al. Protein export from the nucleus. Traffic. 2:2001;684-689.
5. Gorlich D., Kutay U. Transport between the cell nucleus and the cytoplasm. Annu. Rev. Cell Dev. Biol. 15:1999;607-660.
6. Umezawa I., et al. A new antitumor antibiotic, kazusamycin. J. Antibiot. (Tokyo). 37:1984;706-711.
7. Tunac J.B., et al. Novel antitumor antibiotics, CI-940 (PD 114720) and PD 114,721: taxonomy, fermentation and biological activity. J. Antibiot. (Tokyo). 38:1985;460-465.
8. Roberts B.J., et al. In vivo and in vitro anticancer activity of the structurally novel and highly potent antibiotic CI-940 and its hydroxy analog (PD 114,721). Cancer Chemother. Pharmacol. 16:1986;95-101.
9. Yoshida M., et al. Effects of leptomycin B on the cell cycle of fibroblasts and fission yeast cells. Exp. Cell Res. 187:1990;150-156.
10. Wolff B., et al. Leptomycin B is an inhibitor of nuclear export: inhibition of nucleo-cytoplasmic translocation of the human immunodeficiency virus type 1 (HIV-1) Rev protein and Rev-dependent Mrna. Chem. Biol. 4:1997;139-147.
11. Adachi Y., Yanagida M. Higher order chromosome structure is affected by cold-sensitive mutations in a Schizosaccharomyces pombe gene crm1? which encodes a 115-kD protein preferentially localized in the nucleus at its periphery. J. Cell Biol. 108:1989;1195-1207.
12. Nishi K., et al. Leptomycin B targets a regulatory cascade of crm1, a fission yeast nuclear protein, involved in control of higher order chromosome structure and gene expression. J. Biol. Chem. 269:1994;6320-6324.
13. Fukuda M., et al. CRM1 is responsible for intracellular transport mediated by the nuclear export signal. Nature. 390:1997;308-311.
14. Ossareh-Nazari B., et al. Evidence for a role of CRM1 in signal-mediated nuclear protein export. Science. 278:1997;141-144.
15. Fornerod M., et al. CRM1 is an export receptor for leucine-rich nuclear export signals. Cell. 90:1997;1051-1060.
16. Stade K., et al. Exportin 1 (Crm1p) is an essential nuclear export factor. Cell. 90:1997;1041-1050.
17. Kudo N., et al. Leptomycin B inhibition of signal mediated nuclear export by direct binding to CRM1. Exp. Cell Res. 242:1998;540-547.
18. Kudo N., et al. Leptomycin B inactivates CRM1/exportin 1 by covalent modification at a cysteine residue in the central conserved region. Proc. Natl. Acad. Sci. U. S. A. 96:1999;9112-9117.
19. Daelemans D., et al. A synthetic HIV-1 Rev inhibitor interfering with the CRM1-mediated nuclear export. Proc. Natl. Acad. Sci. U. S. A. 99:2002;14440-14445.
20. Newlands E.S., et al. Phase I trial of elactocin. Br. J. Cancer. 74:1996;648-649.
21. Lain S., et al. Accumulating active p53 in the nucleus by inhibition of nuclear export: a novel strategy to promote the p53 tumor suppressor function. Exp. Cell Res. 253:1999;315-324.
22. Vigneri P., Wang J.Y. Induction of apoptosis in chronic myelogenous leukemia cells through nuclear entrapment of BCR-ABL tyrosine kinase. Nat. Med. 7:2001;228-234.
23. Ferrigno P., Silver P.A. Regulated nuclear localization of stress-responsive factors: how the nuclear trafficking of protein kinases and transcription factors contributes to cell survival. Oncogene. 18:1999;6129-6134.
24. Komeili A., O'Shea E.K. Nuclear transport and transcription. Curr. Opin. Cell Biol. 12:2000;355-360.
25. Karin M., et al. NF-κB in cancer: from innocent bystander to major culprit. Nat. Rev. Cancer. 2:2002;301-310.
26. Epinat J.C., Gilmore T.D. Diverse agents act at multiple levels to inhibit the Rel/NF-κB signal transduction pathway. Oncogene. 18:1999;6896-6909.
27. Guttridge D.C., et al. NF-κB controls cell growth and differentiation through transcriptional regulation of cyclin D1. Mol. Cell. Biol. 19:1999;5785-5799.
28. 1-to-S-Phase transition. Mol. Cell. Biol. 19:1999;2690-2698.
29. Beg A.A., Baltimore D. An essential role for NF-κB in preventing TNF-α-induced cell death. Science. 274:1996;782-784.
30. Liu Z.G., et al. Dissenction of TNF receptor 1 effector functions: JNK activation is not linked to apoptosis, while NF-κB activaton prevents cell death. Cell. 87:1996;565-576.
31. Van Antwerp D.J., et al. Suppression of TNF-α-induced apoptosis by NF-κB. Science. 274:1996;784-787.
32. Henkel T., et al. Intramolecular masking of the nuclear location signal and dimerization domain in the precursor for the p50 NF-κB subunit. Cell. 68:1992;1121-1133.
33. Beg A.A., et al. IκB interacts with the nuclear localization sequences of the subunits of NF-κB: a mechanism for cytoplasmic retention. Genes Dev. 6:1992;1899-1913.
34. Ganchi P.S., et al. IκB/MAD-3 masks the nuclear localization signal of NF-κB p65 and requires the transactivation domain to inhibit NF-κB p65 DNA binding. Mol. Biol. Cell. 3:1992;1339-1352.
35. Shoji S., et al. An allosteric drug, o,o′-bismyristoyl thiamine disulfide, suppresses HIV-1 replication through prevention of nuclear translocation of both HIV-1 Tat and NF-κB. Biochem. Biophys. Res. Commun. 249:1998;745-753.
36. Ariga A., et al. Inhibition of tumor necrosis factor-α-induced nuclear translocation and activation of NF-κB by dehydroxymehylepoxyquinomicin. J. Biol. Chem. 277:2002;24625-24630.
37. Matsumoto N., et al. Synthesis of NF-κB activation inhibitors derived from epoxyquinomicin C. Bioorg. Med. Chem. Lett. 10:2000;865-869.
38. Kim I.S., et al. Truncated form of importin α identified in breast cancer cell inhibits nuclear import of p53. J. Biol. Chem. 275:2000;23139-23145.
39. Sengupta S., et al. Negative cross-talk between p53 and the glucocorticoid receptor and its role in neuroblastoma cells. EMBO J. 19:2000;6051-6064.
40. Ryan K.M., et al. Regulation and function of the p53 tumor suppressor protein. Curr. Opin. Cell Biol. 13:2001;332-337.
41. Roth J., et al. Nucleo-cytoplasmic shuttling of the hdm2 oncoprotein regulates the levels of the p53 protein via a pthway used by the human immunodeficiency virus rev protein. EMBO J. 17:1998;554-564.
42. Stommel J.M., et al. A leucine-rich nuclear export signal in the p53 tetramerization domain: regulation of subcellular localization and p53 activity by NES masking. EMBO J. 18:1999;1660-1672.
43. Zhang Y., Xiong Y. A p53 amino-terminal nuclear export signal inhibited by DNA damage-induced phosphorylation. Science. 292:2001;1910-1915.
44. Geyer R.K., et al. The MDM2 RING-finger domain is required to promote p53 nuclear export. Nat. Cell Biol. 2:2000;569-573.
45. Boyd S.D., et al. An intact HDM2 RING-finger domain is required for nuclear exclusion of p53. Nat. Cell Biol. 2:2000;563-568.
46. Giannakakou P., et al. p53 is associated with cellular microtubules and is transported to the nucleus by dynein. Nat. Cell Biol. 2:2000;709-717.
47. Lain S., et al. An inhibitor of nuclear export activates the p53 response and induces the localization of HDM2 and p53 to U1A-positive nuclear bodies associated with the PODs. Exp. Cell Res. 248:1999;457-472.
48. Hietanen S., et al. Activation of p53 in cervical carcinoma cells by small molecules. Proc. Natl. Acad. Sci. U. S. A. 97:2000;8501-8506.
49. Vazquez F., Sellers W.R. The PTEN tumor suppressor protein: an antagonist of phosphoinositide 3-kinase signaling. Biochim. Biophys. Acta. 1470:2000;M21-M35.
50. Carpenter C.L., Cantley L.C. Phosphoinositide kinases. Curr. Opin. Cell Biol. 8:1996;153-158.
51. Maehama T., Dixon J.E. The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-triphosphate. J. Biol. Chem. 273:1998;13375-13378.
52. Datta S.R., et al. Cellular survival: a play in three Akts. Genes Dev. 13:1999;2905-2927.
53. Morris J.Z., et al. A phosphatidylinositol-3-OH kinase family member regulating longevity and diapause in Caenorhabditis elegans. Nature. 382:1996;536-539.
54. Kimura K.D., et al. daf-2, an insulin receptor-like gene that regulates longevity and diapause in Caenorhabditis elegans. Science. 277:1997;942-946.
55. Paradis S., et al. A PDK1 homolog is necessary and sufficient to transduce AGE-1 PI3-kinase signals that regulate diapause in Caenorhabditis elegans. Genes Dev. 13:1999;1438-1452.
56. Andjelkovic M., et al. Role of translocation in the activation and function of protein kinase B. J. Biol. Chem. 272:1997;31515-31524.
57. Meier R., et al. Mitogenic activation, phosphorylation, and nuclear translocation of protein kinase B. J. Biol. Chem. 272:1997;30491-30497.
58. Kops G.J., et al. Direct control of the Forkhead transcription factor AFX by protein kinase B. Nature. 398:1999;630-634.
59. Brownawell A.M., et al. Inhibition of nuclear import by protein kinase B (Akt) regulates the subcellular distribution and activity of the forkhead transcription factor AFX. Mol. Cell. Biol. 21:2001;3534-3546.
60. Brunet A., et al. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell. 96:1999;857-868.
61. Rena G., et al. Phosphorylation of the transcription factor forkhead family member FKHR by protein kinase B. J. Biol. Chem. 274:1999;17179-17183.
62. Nakamura N., et al. Forkhead transcription factors are critical effectors of cell death and cell cycle arrest downstream of PTEN. Mol. Cell. Biol. 20:2000;8969-8982.
63. Biggs W.H., et al. Protein kinase B/Akt-mediated phosphorylation promotes nuclear exclusion of the winged helix transcription factor FKHR1. Proc. Natl. Acad. Sci. U. S. A. 96:1999;7421-7426.
64. Woods Y.L., et al. The kinase DYRK1A phosphorylates the transcription factor FKHR at Ser329 in vitro, a novel in vivo phosphorylation site. Biochem. J. 355:2001;597-607.
65. Brunet A., et al. Protein kinase SGK mediates survival signals by phosphorylating the forkhead transcription factor FKHRL1 (FOXO3a). Mol. Cell. Biol. 21:2001;952-965.
66. Rena G., et al. Roles of the forkhead in rhabdomyosarcoma (FKHR) phosphorylation sites in regulating 14-3-3 binding, transactivation and nuclear targeting. Biochem. J. 354:2001;605-612.
67. Brunet A., et al. 14-3-3 transits to the nucleus and participates in dynamic nucleocytoplasmic transport. J. Cell Biol. 156:2002;817-828.
68. Sato S., et al. Interference with PDK1-Akt survival signaling pathway by UCN-01 (7-hydroxystaurosporine). Oncogene. 21:2002;1727-1738.
69. Tenzer A., et al. The phosphotidylinositide 3′-kinase/Akt survival pathway is a target for the anticancer and radiosensitizing agent PKC412, an inhibitor of protein kinase C. Cancer Res. 61:2001;8203-8210.
70. Colas P., et al. Genetic selection of peptide aptamers that recognize and inhibit cyclin-dependent kinase 2. Nature. 380:1996;548-550.
71. Cohen B.A., et al. An artificial cell-cycle inhibitor isolated from a combinatorial library. Proc. Natl. Acad. Sci. U. S. A. 95:1998;14272-14277.
72. Fabbrizio E., et al. Inhibition of mammalian cell proliferation by genetically selected peptide aptamers that functionally antagonize E2F activity. Oncogene. 18:1999;4357-4363.
73. Butz K., et al. Induction of apoptosis in human papillomavirus-positive cancer cell by peptide aptamers targeting the viral E6 oncoprotein. Proc. Natl. Acad. Sci. U. S. A. 97:2000;6693-6697.
74. Colas P., et al. Targeted modification and transportation of cellular proteins. Proc. Natl. Acad. Sci. U. S. A. 97:2000;13720-13725.